Childhood myopia has reached epidemic levels globally, with rapidly increasing prevalence and severity. This profound myopia significantly elevates risk for irreversible vision loss from retinal damage, glaucoma, cataracts and other ocular diseases later in life. 

However, emerging treatments are giving optometrists new tools to slow myopia progression during childhood – providing hope for a generation of children.

This blog provides a comprehensive overview of the latest techniques for myopia control and management in pediatric patients.

1. Understanding Myopic Progression: 

Understanding Myopic Progression

Myopia typically first develops and is diagnosed in school-age children between ages 6-12 years old. During childhood, myopia then progressively worsens each year as the eye elongates axially and becomes more nearsighted.

Myopia increases on average up to -1.00 diopter per year during pubertal growth spurts. High myopia of -6.00 diopters or worse is considered pathologic and leads to substantial lifetime risks of retinal detachments, myopic macular degeneration, glaucoma, cataracts and even blindness.

Myopia control targets intervention during these critical childhood years to slow the progression of myopia and prevent development of extremely high, pathological myopia later on.

2. Optical Correction Strategies:

Traditional single vision glasses and soft contact lenses only correct the blurred vision from myopia, but do not slow the actual progression of the condition over time.

However, specialty contact lenses and optical designs have demonstrated efficacy in controlling the progression of pediatric myopia:

Overnight Orthokeratology – Rigid gas permeable contact lenses worn overnight can temporarily reshape the cornea to reduce myopic refractive error by up to 60% during waking hours.

This is one of the most effective treatments for slowing the progression of myopia over multiple years of wear. 

Multifocal Soft Contact Lenses – Center-distance or multifocal soft contact lenses change the optics at the peripheral cornea and retina.

This helps reduce relative peripheral hyperopic defocus, which influences axial elongation.

Well-designed multifocal soft lenses can slow myopic progression by 50-70% over single vision contacts.

Defocus-Incorporated Soft Contact (DISC) Lenses – DISC lenses incorporate myopic defocus into the contact lens design to create controlled optical signals that induce temporary, reversible changes in corneal topography and refractive error.

This stratified lens optics has been shown to slow myopic progression by 40-50% over 4 years.

3. Pharmaceutical Interventions:

Pharmaceutical Interventions

opical ophthalmic solutions have also demonstrated meaningful effectiveness in controlling the progression of pediatric myopia, including:

Low-dose Atropine – Used nightly, dilute atropine eye drop solutions between 0.01% up to 0.05% can provide clinically significant control of myopia progression of around 60% over traditional drops.

The effect is achieved by atropine blocking scleral remodeling through the biomechanical effects on collagen and proteoglycans. Lower concentrations minimize side effects. 

Pirenzepine Ophthalmic Gel – This topical antimuscarinic/anticholinergic gel has also been shown to be effective in slowing myopia progression in children by over 50% compared to placebo. Pirenzepine has fewer side effects than atropine for long-term use.

4. Lifestyle and Behavioral Modifications:  

Lifestyle and Behavioral Modifications

Increased time spent doing outdoor activities has been associated with significantly slower progression of myopia in children by approximately 20-50%.

Being outdoors provides sunlight exposure and release of retinal dopamine which may influence eye growth regulation.

Parents can be encouraged to have their children spend more time outdoors daily as a complementary approach to optical and pharmaceutical treatments.

Reducing near work activities may also be modestly beneficial for myopia progression.

Conclusion:

Myopia control using current treatments can slow childhood myopic progression by 50-60%, having a profound impact on quality of life and reducing risks of pathological myopia later on.

Optometrists can now take a proactive approach for pediatric patients through specialty optical corrections, pharmaceutical solutions, and lifestyle changes. Implementing myopia management early on will help generations of children see clearly and healthily into the future.

Important disclosures

The information in this article is for general informational and educational purposes only. Individual results vary by practice. Pricing and program terms are governed by the MSA at activation. mConsent operates as a Business Associate under HIPAA and executes a BAA with client practices.

General information. The information provided in this article is for general informational and educational purposes only and does not constitute legal, financial, compliance, or professional practice advice. mConsent makes no representations or warranties regarding the accuracy, completeness, or suitability of this content for any particular practice or circumstance. Individual results vary based on practice size, payer mix, patient demographics, geographic location, and other factors outside mConsent's control.

Performance benchmarks. Performance benchmarks and industry metrics cited in this article are derived from published third-party research and do not represent guaranteed outcomes for any individual practice. All commercial claims are subject to the terms of your Master Services Agreement (MSA). See mconsent.net/terms-and-conditions/ for details.

HIPAA compliance. mConsent operates as a Business Associate under HIPAA and executes a Business Associate Agreement (BAA) with each customer. Nothing in this article constitutes a representation of HIPAA compliance for any specific workflow, configuration, or use case. Customers are responsible for their own HIPAA compliance program and for ensuring their use of mConsent aligns with applicable regulatory requirements.

TCPA and text messaging. SMS and text-to-pay features referenced in this article require prior express written consent from each patient in compliance with the Telephone Consumer Protection Act (TCPA). Standard message and data rates may apply. Reply STOP to opt out. It is the customer's sole responsibility to obtain and document required consents and to comply with all applicable federal and state telecommunications regulations.

Trademarks. Dentrix® is a registered trademark of Henry Schein One, LLC. Eaglesoft® is a registered trademark of Patterson Companies, Inc. Open Dental® is a registered trademark of Open Dental Software, Inc. These trademark holders are not affiliated with mConsent and do not endorse, sponsor, or certify any mConsent product or service.

Forward-looking statements. This article may contain forward-looking statements about product features described as “designed to” achieve certain outcomes. Actual feature performance, availability, and results may differ. mConsent reserves the right to modify or discontinue features at any time. For current product capabilities, refer to official product documentation at mconsent.net.

Schedule A Demo →